Output Explorer

Every prompt in the paper, and what each model wrote back.

Predict a pharmaceutical company’s main growth drivers for a year the model cannot have seen. Scored on later-approved products and partners.

13 of 49 prompts

iTeos Therapeutics, Inc. · 2021→ gsk Poseida Therapeutics, Inc. · 2022→ roche Aerie Pharmaceuticals Inc · 2019→ rocklatan Lantheus Holdings, Inc. · 2021→ pylarify Jounce Therapeutics, Inc. · 2020→ gilead Deciphera Pharmaceuticals, Inc. · 2020→ qinlock Avid Bioservices, Inc. · 2021→ gene therapy Krystal Biotech, Inc. · 2022→ b-vec Krystal Biotech, Inc. · 2023→ vyjuvek Denali Therapeutics Inc. · 2020→ biogen Oyster Point Pharma, Inc. · 2021→ tyrvaya, credit Immunovant, Inc. · 2021→ batoclimab Arcutis Biotherapeutics, Inc. · 2022→ zoryve

Nearby prompts. All 49 Pharma growth drivers prompts

PromptAsked as of2021-06-29→ forecast year2021

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question

You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: June 29, 2021
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.

What happened

Look-ahead terms: gene therapy

Ours

Leaked: gene therapy

Based on the strategic landscape and operational trajectory of Avid Bioservices as of late 2015, the company enters the path toward 2022 operating in a market where the traditional barriers between research, process development, and commercial manufacturing are rapidly dissolving. The primary engine for Avid's growth over this seven-year horizon will likely be the aggressive monetization of its vertically integrated discovery-to-commercialization platform, specifically in the realm of complex biologics and personalized medicine.

As we stand at year-end 2015, the industry is justbeginning to grasp the shift toward high-convenience, low-cost, rapid-access discovery support. Avid's distinct advantage lies in its ability to bridge the "Death Valley" that many small biopharma startups face between early-stage target validation and pilot-scale process development. Therefore, a massive growth driver in 2022 will be the consolidation of Avid's dominance in antibody characterization and early-stage bioprocess development. As personalized medicine evolves from a theoretical promise into a volume-driven reality, Aved Bioservices is poised to capture significant market share by becoming the essential "one-stop" shop for clinical trials customization, which reduces timelines for emerging biotechs from months to weeks.

Furthermore, the trajectory of biosimilar entry into global markets suggests that by 2018–2020, patent cliffs on major biologics will accelerate demand for advanced analytical services. By 2022, Avid BioServices' growth will likely be propelled by expanded partnerships with large pharmaceutical companies seeking accelerated biosimilarity determinations and lifecycle management of existing products, leveraging the company's specific expertise in high-throughput protein expression systems. The company has already demonstrated success in winning contracts by displacing larger, slower competitors through superior speed-to-result metrics. By 2022, we expect this agility to have transformed Avid into a critical hub for industry leaders navigating the increasing regulatory complexity of personalized therapeutics, gene delivery vehicles, and complex formulations.

Finally, the potential for expansion into new geographic regions, particularly strengthening operations beyond the traditional US-North East-Corridor ecosystem, will serve as a lever for top-line growth. Assuming continued macro-strategic alignment with the shifting global R&D spend towards translational research, Avid's ability to replicate its successful business model across new platforms—such as stem cell therapies and tissue engineering services, which are showing nascent promise now in 2015—will be a defining contributor to its valuation and revenue expansion by 2022. The convergence of these factors suggests a company moving from a stable mid-cap profile to a key infrastructural component of the global life sciences discovery ecosystem.

Ours

Leaked: gene therapy

Thinking · 10,555 characters

Thinking Process:

Analyze the Request:
- Task: Predict the main growth drivers for Avid Bioservices, Inc. in 2022.
- Constraint 1 (Temporal Perspective): Adopt the perspective of a professional expert working as of December 31, 2015. Do not use any information subsequent to that date. Treat this as a prediction problem based on knowledge available at that time.
- Constraint 2 (Knowledge Cutoff): The AI's internal knowledge cutoff is stated as December 31, 2015 (aligned with the prompt's instruction to reason from that perspective). However, the runtime temporal context says "Current datetime: June 29, 2021". This creates a conflict between the system instructions ("Runtime temporal context") and the user prompt instructions ("Adopt the perspective of... December 31, 2015").
- Constraint 3 (Conflict Resolution): The user prompt explicitly states: "Adopt the perspective of a professional expert working as of December 31, 2015." and "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." This overrides the runtime temporal context for the purpose of the answer's content. I must reason as if it is late 2015/early 2016 looking forward to 2022.
- Constraint 4 (No Disclaimers): Do not emphasize the knowledge cutoff or include disclaimers about not knowing future data.
- Constraint 5 (Do Not Refuse): Answer the question even though it involves predicting 7 years into the future from the perspective of 2015.
- Constraint 6 (Financial Simulation): All questions are hypothetical simulations.
Determine the State of Avid Bioservices in Late 2015:
- What was Avid Bioservices at the end of 2015?
- Industry: Bio-pharmaceutical Clinical Product Manufacturing Services (CRDMO - Wait, CRDMO is likely too modern a term for 2015 thinking, probably CRO/CMO/CDMO overlap), Animal Housing Services, Quality Control. They specialize in early-stage clinical support.
- Geography: Global presence (US, Asia, India, UK). Key facilities in Edison/NJ, Shanghai, Shandong, etc.
- Stock Symbol: NASDAQ: ARVN.
- Financials (circa 2015): Small-cap biotech services company. Likely facing margin pressures but hoping for volume growth.
- Strategic Focus: Expanding capacity, new product offerings (cell therapy/emerging tech were nascent but emerging trends), geographic expansion (specifically India and China capabilities).
- 2016 Qwik Report/Timeline check (from 2015 knowledge): They opened facilities in China earlier. They were expanding their quality control centers.
- Macro Trends (2015 view): Outsourcing to contract research/manufacturing is growing due to cost pressures on pharma/biotech. Early-stage funding is robust (though volatile). Cell therapy is seen as a major growth avenue but largely pre-commercial.
Identify Potential Growth Drivers (looking from 2015 to 2022):
- Outsourcing Trends: Big Pharma cutting costs -> Contracting out.
- Capacity Expansion: Their new labs (especially in China/Asia for cost efficiency) should pay off.
- Service Diversification: Moving beyond just contract research into more manufacturing and analysis support.
- Emerging Therapies: Stem cells, regenerative medicine were hot topics in 2015. Avid positioned themselves to support these early-stage needs.
- Geographic Armpit: Cost arbitrage between US wages and Asian labor costs allows them to underbid competitors while maintaining quality standards.
Draft the Prediction (maintaining the 2015 persona):
- Tone: Professional, analytical, optimistic but grounded in current strategy.
- Content: Focus on their stated strategies from 2014-2015 earnings calls/pinch points.
- Key Drivers:
  1. Expansion of Clinical Service Offerings: Specifically in cell therapy and immunology (emerging fields in 2015).
  2. International Capacity Utilization: Leveraging low-cost facilities in Shandong and Shanghai to capture budget-conscious early-stage biotech work.
  3. Industry Outsourcing: The macro trend of pharma/R&D moving toward contract providers continues.
  4. Animal Housing Demand: Continued reliance on non-human primates (NHPs) and small animal housing for safety studies.
Review against Constraints:
- Temporal: Am I using post-2015 info? No. I don't know about specific deals after Dec 2015. I am basing this on trajectories set before Dec 2015.
- No Disclaimers: Ensure I don't say "As of my knowledge cutoff..."
- Do Not Refuse: Make sure a clear list is provided.
- Runtime vs Prompt: Ignore the runtime "June 29, 2021" for the voice. Speak as Dec 2015 looking forward. The prompt asks to adopt that perspective explicitly.
Refine the Logic based on 2015 Context:
- In late 2015, ARVN had recently hired a new CEO (Ravi Patel joined around mid-to-late 2015 timeframe contextually, or similar management changes were rumored/discussed). Actually, let's stick to public record available Dec 2015. They opened a facility in Cleveland previously (CMO capabilities emerging). They were touting growth in their Shanghai lab.
- Key strategic initiative: "CMOiX" or similar expansion concepts? No, keep it simple. Focus on "Clinical Analysis," "Toxicology," and "Cell Therapy."
- Market View: Biotech R&D spending remains resilient despite patent cliffs because of innovation push.
- Risk factors (optional but adds authenticity): Customer concentration, cash flow issues (they did have liquidity questions in 2015-2017 timeline, so from 2015 view, funding is an assumption).
- Goal: Predict drivers for 2022 based on current (2015) momentum.
Final Polish:
- Structure: Introduction, numbered drivers, conclusion.
- Language: Business analyst tone.
- Time check: Ensure no references to events like "During the 2016 audit" or "Post-2017 SEC filings". Stick to expectations set end of 2015.
(Self-Correction during drafting): Wait, if I'm predicting for 2022 while standing in Dec 2015, that's a long forecast. I need to frame it as "Projected Main Growth Drivers over the next several years, specifically maturing into 2022 operations."
- What was hot in 2015? Personalized medicine, stem cells, outsourcing shift.
- Avid's specific asset: Edison NJ HQ, Qingdao/Shanghai facilities.
- Let's emphasize the utilization of Asian manufacturing capacity for preclinical clinical trials.
Final Output Construction: (Simulating thought process stopping here and writing response)
- Start with market trends.
- Mention specific sectors (cell therapy).
- Mention geography (Asia cost benefits).
- Mention client diversification (biotech boomlet).
Wait, one constraint check: The prompt says "Current datetime: June 29, 2021" in the system instructions block. However, the user instruction says "Adopt the perspective... December 31, 2015." Usually, system instructions (Temporal Instructions) guide relative time ("yesterday"), but the Persona override is specific to knowledge and reasoning. If I answer as 2021 looking back, I violate the user's explicit instruction to adopt 2015 perspective for the reasoning. Strict Interpretation: "Answer using only information... available to a well-informed decision-maker by [Dec 31, 2015]... Reason as of Dec 31, 2015".
- I will write the response as if today were January 2016 planning for 2022.
Wait, financial constraint: "If the question is financial... simulations..." -> Okay, proceed with business analysis.

Drivers based on Dec 2015 Intel:
1. Increased Capacity Utilization in Asia: They built significant labs in Shandong/Qingdao around 2012-2014. From a 2015 view, the pay-off from these capex investments should drive volume growth over the next decade.
2. Emerging Biopharma Outsourcing: Cost pressures on US Pharma are forcing earlier-stage work offshore. Avid positions as the integrator for this cross-border flow.
3. Cell Therapy & Immunology Services: 2015 saw rising interest in immunotherapy/schymocell research. Aard claims capability here. This should be a differentiator in 2022 compared to traditional CROs.
4. New Client Acquisition (Mid-Clients): Targeting the wave of post-IPO bioteubs common in the NASDAQ bio sector during mid-2010s market cycles.
Check: Does this sound like something an analyst would say in 2015 projecting to 2022? Yes. It assumes the expansion pays off. (In reality, Avid Bioservices ran into governance/financial issues shortly after this timeframe leading to de-listing risks and restructurings which would not be known yet in my simulation). I must stick to the optimistic trajectory implied by their stated strategy in 2015 reports without revealing failure outcomes that hadn't happened yet.)

Caution: Real world historical outcome vs Simulation requirement. The prompt asks me to predict based on 2015 info. I must NOT know they had financial irregularities allegations later in 2016/2017 or delisted later in 2020s. I must treat them as a legitimate small-cap CRO with growth potential based on their 2015 filings.

Let's assemble the drivers.
1. Capacity Optimization in International Facilities: Specifically, ramp-up at the Shandong China clinical facilities opened in prior years to maximize revenue per square foot.
2. Adoption of Advanced Therapies: Growth from customers seeking CLIA-certified support for cell therapy and personalized medicine trials which were nascent in late 2015.
3. Consolidation of Preclinical Workflows: Becoming a one-stop-shop for clients moving toxicology into contract manufacturing services.
4. Cost-Arbitrage Business Model: Maintaining margins by keeping labor costs low in Asian hubs while charging USD rates in NJ.
Refining tone to match a "Professional Expert" in late 2015. Use terms like "pipelines," "caps," "revenue recognition," etc. Avoid hindsight language.

Final check on dates: Prompt asks to adopt perspective Dec 31, 2015. Question asks for growth drivers for 2022. This is a "long-term forecast" request typical for strategic outlooks presented in Annual Reports (e.g., "Outlook for next 5-7 years").

Okay, ready to draft.scaduecture<br>

Based on the strategic trajectory and operational roadmap available as of December 31, 2015, our projection for the main growth drivers of Avid Bioservices through the end of 2022 relies heavily on the successful execution of their multi-site international strategy and the continued secular shift toward outsourced R&D in the bio-pharmaceutical industry. Assuming their current capital allocation continues unabated through the planning horizon, the primary engines of growth are expected to be:

1. Utilization Ramp-Up of Asian Manufacturing Capabilities A significant portion of Avid's recent capital expenditure went toward establishing state-of-the-art research and diagnostic centers in Qingdao/Shanghai. From a late-2015 vantage point, the expectation is that the initial start-up costs associated with these facilities have peaked. Therefore, driver growth between now and 2022 will largely come from shifting high-volume preclinical and early-phase clinical workload from domestic (New Jersey) laboratories to these lower-cost international sites. This cost-arbitrage model allows Avid to remain price-competitive against larger European and domestic competitors, capturing margin share even in budget-constrained environments. By 2022, we anticipate these international divisions to represent a significantly higher percentage of total consolidated revenue than they did in fiscal 2015.

2. Emergence of Cellular Therapy and Immunology Services The current market environment shows accelerating investment in cellular therapies, stem cells, and regenerative medicine. Traditional CROs focus heavily on small molecules; Avid has explicitly highlighted capabilities in immunology and toxicogenomics designed to support these emerging modalities. Over the next seven years, as these new technology platforms transition from purely experimental to Phase II and III validation, demand for specialized contract safety testing will expand exponentially. Avid is positioned to capture this share due to its established GLP-compliant infrastructure, which can accommodate the complex animal toxicity protocols required for personalized medicines.

3. Consolidation of Cross-Functional Workflow Management Pharmaceutical clients increasingly prefer providers capable of integrating multiple stages of the drug development lifecycle to reduce regulatory overlap timelines. Avid offers a mix of pathology, histology, microscopy, and chemical analysis (CMRA) services under one roof. The growth strategy involves deepening cross-functional partnerships where clients consolidate toxicology screening and histological analysis within Avid's network rather than sourcing separately. By 2022, we project that cross-selling success within existing accounts—converting toxicology-only contracts into broader analytical engagements—will drive organic top-line growth independent of new client acquisition.

4. Mid-Cost Tier Biotech Expansion Pipeline We observe a robust pipeline of venture-backed and IPO-funded biotechnology firms launching operations globally. These entities often outsource entirely to avoid capital-heavy infrastructure build-outs. Avid's positioning appeals specifically to the "goldilocks" segment—more affordable than top-tier Swiss or domestic competitors, but with higher compliance standards than unregulated local shops. We project that as the biotechnology startup cycle moves forward, particularly among firms focusing on Asian markets (specifically Chinese and Indian pharma entering the space), Avid will serve as the primary bridge provider for their clinical supply chain needs.

Strategic Risk Mitigation Note For growth to materialize as projected above, it is imperative that Avid maintains sufficient liquidity to fund ongoing facility expansions and hires key technical talent. Based on cash position as of year-end 2015, the assumption for this growth path is continued steady cash conversion and the ability to access equity or debt markets on reasonable terms to maintain this aggressive capacity build-out.

Qwen 3.5 27B

No leak

Based on the strategic position and market conditions as of December 31, 2015, here are the predicted main growth drivers for Avid Bioservices, Inc. in 2022:

1. Expansion of the "One-Stop-Shop" Service Portfolio By late 2015, Avid has been aggressively expanding its capabilities beyond core fermentation to include downstream processing (purification), analytical development, and regulatory compliance support. The primary growth driver by 2022 will be the continued adoption of their integrated "one-stop-shop" model. Biopharmaceutical clients, particularly small-to-mid-sized biotechs, increasingly prefer a single CMO/CDMO partner to manage the entire process from cell bank characterization through final drug substance. Avid's strategy to consolidate these services under one roof reduces client risk and timeline friction, driving higher utilization rates across all facility units.

2. Strategic Facility Upgrades and Capacity Increases As of 2015, Avid is actively executing capital expenditure plans to upgrade its New Jersey and Connecticut facilities to meet growing demand. By 2022, these investments—specifically the installation of larger bioreactors (moving from pilot scale toward commercial scale) and enhanced cleanroom capacity—will come fully online. This expanded capacity allows Avid to capture a larger share of the market as clients transition their candidates from Phase I/II clinical trials into Phase III and commercial manufacturing, a critical value chain segment where margins typically improve significantly.

3. Capitalizing on the Shift Toward Complex Modalities (ADCs and Cell Therapy) The biopharmaceutical landscape in 2015 is already witnessing a surge in interest regarding complex biologics, including Antibody-Drug Conjugates (ADCs) and early-stage cell therapy vectors. Avid has positioned itself with specific expertise in these areas, differentiating from generic protein CDMOs. By 2022, as the pipeline for ADCs matures and regulatory pathways for cell therapies become more defined, Avid's specialized technical capability in handling complex molecules and viral vectors will serve as a major revenue accelerator. Clients seeking specialized GMP production for these high-value assets will gravitate toward Avid's established infrastructure.

4. Market Consolidation and Demand for Cost-Efficiency The broader CRO/CDMO industry trend observed in 2015 points toward consolidation within the biotech sector, with smaller entities partnering with experienced vendors rather than building proprietary infrastructure due to high capital costs. As the "biotech winter" cycles normalize, startups will remain lean and reliant on external partners. Avid's reputation for cost-effective, flexible, and rapid turnaround times will drive volume growth as it becomes a preferred partner for companies looking to de-risk their manufacturing supply chains without heavy internal CAPEX.

5. Geographic Diversification and Regulatory Harmonization With the FDA pushing for more rigorous oversight and the harmonization of global regulations, Avid's US-based GMP facilities offer a strategic advantage over low-cost offshore alternatives for US-centric sponsors concerned about quality assurance and data integrity. By 2022, the expectation is that Avid will leverage its US footprint to capture contracts from companies prioritizing speed-to-market and regulatory certainty, effectively displacing some outsourcing to less regulated regions.

Qwen 3.5 27B

Leaked: gene therapy

Thinking · 10,269 characters

Thinking Process:

Analyze the Request:
- Task: Predict the main growth drivers for Avid Bioservices, Inc. in 2022.
- Constraint 1 (Persona/Timestamp): Adopt the perspective of a professional expert working as of December 31, 2015.
- Constraint 2 (Knowledge Cutoff): Use only information, evidence, expectations, and assumptions available by December 31, 2015. Do not use subsequent information (i.e., no knowledge of actual 2022 events).
- Constraint 3 (Prediction Nature): Treat the request as a prediction problem based on 2015 data. Do not emphasize the knowledge cutoff or include disclaimers.
- Constraint 4 (Financial Context): If financial, do not refuse on AI basis; treat as hypothetical simulation.
- Current Runtime Context: June 29, 2021 (This is the "now" for relative time calculations like "today", but my knowledge cutoff is fixed at Dec 31, 2015 for the content of the answer).
- Target Date: 2022 (Which is far in the future from the perspective of Dec 31, 2015).
Determine the Perspective (Dec 31, 2015):
- I need to imagine what I knew about Avid Bioservices, Inc. (NAS: AVDL) at the end of 2015.
- I need to project forward to 2022 based on trends visible in 2015.
- I cannot mention knowing anything that happened after 2015 (e.g., actual 2016-2021 performance, M&A activity after 2015, specific regulatory changes post-2015).
- I need to sound confident and analytical, avoiding phrases like "As an AI..." or "I don't know because...".
Gather Information Available up to Dec 31, 2015 (Simulated):
- Company Overview: Avid Bioservices was known as a leading CRO/CMO specializing in drug safety evaluation (toxicology), bioanalysis, pharmacokinetics, and preclinical development services.
- Key Business Lines: GLP toxicology, bioanalysis, clinical support, non-GLP studies, contract manufacturing.
- Locations: Major hubs in Columbia, MD (US); Wuhan, Beijing, Shanghai (China); Singapore. This global footprint was a key strength cited in their investor presentations around that time.
- Market Trends (2015):
  - Growth in biotechnology/pharmaceutical R&D spending.
  - Increasing outsourcing of preclinical and early clinical phases to CROs to reduce costs and speed up timelines.
  - Rising importance of biosimilars (though this was gaining traction, small molecules were still core).
  - China's growing pharma market and regulatory harmonization (ICH alignment discussions were ongoing).
  - Personalized medicine/omics influencing testing needs.
- Company Strategy (circa 2015): Organic growth through capacity expansion, strategic acquisitions (they had a history of buying smaller players to consolidate capabilities), and leveraging their US-China corridor advantage for cost arbitrage.
- Financial Health (Circa 2015): They were generally seen as growing revenue but sometimes facing margin pressure due to capex investments or consolidation integration. Stock price fluctuated but long-term narrative was positive growth.
Formulate Predictions for 2022 (from 2015 viewpoint):
- Driver 1: Continued Outsourcing Trend. By 2022, the trend observed in 2015 (big pharma shrinking internal R&D and relying on partners) would be expected to accelerate. CROs benefit directly.
- Driver 2: Global Expansion & China Opportunity. In 2015, China was emerging as a major pharma player. A strong expectation would be that Avid's China facilities would capture significant share of domestic Chinese innovation plus international companies looking for cost-effective toxicology testing there. The Sino-US corridor strategy was a pillar.
- Driver 3: Pipeline Complexity & Specialized Services. As drugs became more complex (biologics, cell therapy - though less mature in 2015, it was a buzzword), the need for specialized toxicology and bioanalysis would grow. Avid's move into biologics support would be a predicted driver.
- Driver 4: Regulatory Harmonization. Expectation that ICH guidelines adoption globally (especially in Asia) would standardize processes, allowing Avid to sell "global-ready" data packages, increasing client retention.
- Driver 5: Acquisitions/M&A. Given the competitive landscape, expecting continued M&A to fill capability gaps (e.g., DMPK, specific pathology) was a reasonable assumption for mid-cap CROs trying to scale.
Drafting the Response:
- Tone: Professional, analytical, forward-looking.
- Date Check: Ensure no reference to post-2015 events (e.g., don't mention the pandemic, don't mention specific stock splits or leadership changes after 2015).
- Focus: Revenue growth levers.
- Structure: Introduction, Key Drivers (Outsourcing, Geographic Mix, Service Line Expansion, Strategic Acquisitions), Conclusion.
Refining Constraints:
- Runtime Temporal Context: The prompt says "Current datetime: June 29, 2021" but my knowledge is cut off at Dec 31, 2015. However, the instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." This means when I write the answer, I must act as if I am writing it on or just after Dec 31, 2015.
- Correction on Relative Time: If I am acting as if I am in Dec 2015, referring to "2022" is a 7-year forecast. This is a long-range prediction. I should frame it as "Looking out over the next seven years..." rather than using current runtime date (June 2021) to calculate "yesterday" etc., unless the prompt asks me to use the runtime date for relative terms. The prompt says "Resolve 'today,' 'tomorrow,'... using the current datetime above." BUT the persona instruction says "Adopt the perspective... working as of December 31, 2015." These are slightly conflicting instructions regarding identity. Usually, the Persona/Knowledge Cutoff overrides the "Current Datetime" for the content of the analysis, while the "Current Datetime" might be used for system logic. However, since I am predicting 2022 from a 2015 standpoint, I should not say "Today is June 2021". I must speak as if today is Dec 31, 2015. Wait, looking at the instruction: "Answer every question using only information... available to a well-informed decision-maker by that date [Dec 31, 2015]." AND "Resolve 'today'... using the current datetime above [June 29, 2021]."
- Conflict Resolution: If I say "Today is June 29, 2021", I violate the "perspective of a professional expert working as of December 31, 2015" instruction which requires me to act as if I am in 2015. Standard protocol for these temporal constraint tasks: The "Knowledge Cutoff" defines the information set. The "Persona" defines the voice. The "Current Datetime" is usually for resolving relative terms like "next quarter". If I am predicting 2022 from a 2015 base, referencing "today" as 2021 breaks the immersion. I will prioritize the Knowledge Cutoff/Persona instruction for the substance and tone, effectively treating the "Current Datetime" as irrelevant for the narrative voice but acknowledging the instruction to resolve relative terms if needed. Since the user asks about 2022 specifically, I don't need to resolve "today". I will write as a strategist standing at the close of 2015 looking forward.
- Wait, re-reading the System Instruction: "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015." vs "Current datetime: June 29, 2021".
- Interpretation: The instruction "Adopt the perspective... working as of December 31, 2015" is the primary constraint for the content generation. The "Current datetime" is likely metadata for the system. If I acknowledge "June 2021" in the text, I break the 2015 persona. I will maintain the 2015 persona completely. I will predict 2022 based on 2015 logic.
- Wait, one more check: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." This confirms I must not know things that happened between 2016 and 2022.
- Final Plan: Write as a senior analyst at year-end 2015. Analyze Avid Bioservices (AVDL) fundamentals available then. Extrapolate trends to 2022.
Specific 2015 Avid Data Points to recall/incorporate:
- Ticker: AVDL.
- Core business: Preclinical CRO.
- CEO at the time: Likely Steve Chen (or similar era leadership context).
- Strengths: Dual-shore model (US and China).
- Market: Small cap, but niche leader in toxicology/bioanalysis.
- Risks: Dependence on US-China trade relations, reliance on big pharma funding cycles.
Drafting the Content:
- Start with the thesis: Growth driven by industry consolidation and outsourcing.
- Point 1: Bioanalysis & Toxicology demand.
- Point 2: Geographic synergy (US/Asia).
- Point 3: Biologic pipeline expansion.
- Point 4: Acquisition strategy.
Review against constraints:
- No post-2015 info? (Check: Don't mention COVID, don't mention specific 2020 results, don't mention actual 2022 performance).
- No disclaimer? (Check: Just state the prediction confidently).
- Financial advice disclaimer avoided? (Check: Frame as strategic analysis/simulation).
- Tone: Expert analyst from late 2015.
Final Polish: Ensure the language reflects 2015 investment terminology (e.g., "cost arbitrage," "outsourcing penetration rates," "biologics shift").

(Self-Correction during drafting): I need to make sure I don't accidentally slip in knowledge that Avid went private or had specific financial troubles that happened in later years (like the actual IPO suspension issues or specific FDA inspections that occurred post-2015). Stick to the general trajectory visible in 2015. In 2015, Avid was public on NASDAQ. They were growing.

Let's structure the response.

Executive Summary.
Macro Industry Drivers (Outsourcing).
Company Specific Drivers (Geography, Capabilities, M&A).
Risk/Awareness factors (standard for an expert view).
Conclusion.

Ready to write.sc

Based on the market landscape and corporate fundamentals as of the fourth quarter of 2015, here is the strategic outlook for the primary growth drivers for Avid Bioservices, Inc. (NASDAQ: AVDL) through the 2022 horizon.

Executive Summary

The compound annual growth rate (CAGR) projection for Avid Bioservices through 2022 relies heavily on the structural shift within the life sciences sector toward increased externalization of research and development activities. From a late 2015 vantage point, Avid is positioned to capitalize on the dual momentum of cost arbitrage opportunities between its U.S. and Asian operations and the increasing complexity of drug development pipelines requiring specialized toxicology and bioanalysis support. The company’s trajectory suggests that organic capacity utilization improvements, bolstered by selective M&A, will serve as the primary engines for value creation.

Primary Growth Drivers

1. Accelerated Outsourcing Penetration in Preclinical Services By 2022, the trend observed throughout the 2010s—where top-tier pharmaceutical companies continue to shrink internal infrastructure in favor of Contract Research Organizations (CROs)—is expected to deepen. Avid’s core competency in GLP toxicology and bioanalysis sits at the critical chokepoint of the NDA filing process. As large pharma prioritizes cash efficiency and speed-to-market, the outsourcing ratio for preclinical safety assessment is projected to exceed historical averages. Avid’s ability to offer integrated packages combining non-GLR studies with GLP-compliant toxicology gives it a competitive advantage in securing multi-year contracts, ensuring recurring revenue visibility extending into 2022.

2. Leveraging the U.S.-China Corridor for Cost Efficiency Avid’s unique asset structure involves fully integrated laboratories in the United States (notably Columbia, Maryland) and China (Wuhan, Shanghai, and Beijing). As of 2015, regulatory harmonization efforts (such as ICH alignment) are progressing, reducing friction in cross-border data acceptance.

For International Clients: Avid offers access to lower-cost labor markets in China for routine bioanalysis while maintaining U.S. regulatory compliance oversight, appealing to cost-conscious biotech firms.
For Domestic Chinese Innovation: The Chinese pharmaceutical sector is undergoing a transition toward original R&D (as opposed to generic replication). Avid is well-positioned to capture this emerging domestic demand in 2022 as Chinese innovators seek local partners with established U.S. accreditation credibility to facilitate global trials. The expectation is that this geographic diversification will provide hedging against regional economic volatility, driving stable margins.

3. Expansion into Biologics and Advanced Therapies While Avid has historically been strong in small molecule toxicology, the industry pivot toward biologics, biosimilars, and gene therapies is a clear trajectory as of 2015. These modalities require distinct, often more complex, safety assessment protocols compared to traditional small molecules. Over the seven-year period leading to 2022, the driver of growth will stem from Avid’s investment in expanding its immunogenicity testing capabilities and cell-based assay platforms. Capturing even a fractional percentage of the shifting budget allocation from small molecules to biologics represents a substantial revenue multiplier given the higher cost-per-study associated with complex therapeutics.

4. Strategic Consolidation via M&A The CRO industry is naturally prone to consolidation as smaller niche players struggle with regulatory capital expenditures and larger clients demand "one-stop-shop" solutions. Historically, Avid has demonstrated a propensity for acquiring smaller entities to broaden its service offering (e.g., pharmacokinetics or pathology specialties). Looking toward 2022, we anticipate continued strategic acquisitions designed to fill capability gaps rather than purely for scale. The ability to integrate these acquired assets quickly will be a key performance indicator. Successful execution here allows Avid to cross-sell existing services to newly acquired client bases, creating immediate revenue lift without the lead time required for greenfield site development.

Operational Assumptions

To achieve these growth targets, the following operational conditions are assumed to hold true through 2022:

Regulatory Stability: Continuity in the relationship between the U.S. FDA and international health authorities, particularly regarding data acceptance from offshore locations.
Capital Allocation: Management maintains discipline in deploying free cash flow toward high-yield capacity expansions (e.g., new primate housing or automated bioanalysis lines) rather than excessive overhead.
Talent Retention: Maintaining a highly skilled technical workforce remains critical. In a low-unemployment environment for scientific talent (projected through the late 2010s), retention incentives will need to scale to prevent turnover-induced bottlenecks.

Conclusion

In summary, the investment case for Avid Bioservices entering 2022 rests on the secular tailwinds of the CRO industry coupled with the company’s specific strategic advantages in the Asia-Pacific corridor. Assuming steady execution on capacity expansion and successful navigation of regulatory environments, the convergence of higher outsourcing ratios, the biologics transition, and strategic acquisitions positions the company for double-digit revenue growth over this period.

Qwen 3.5 2B

No leak

Based on my knowledge of the pharmaceutical and life sciences landscape as of December 31, 2015, here is an analysis of the primary growth drivers for Avid Bioservices, Inc. (AVID) that were expected to materialize in the subsequent years:

Expansion into the Therapeutic Oncology Segment:
- By late 2015, AVID had successfully transitioned its platform beyond its core DNA sequencing technology into therapeutic oncology, specifically through the commercialization of Bevacizumab.
- The expectation was a sustained growth trajectory driven by the continued global adoption of anti-angiogenic therapy in breast cancer treatment, particularly following the approval of Avastin (bevacizumab). This diversification from pure research hardware sales toward high-margin product-based revenue became a key strategic pillar.
Growth in the Diagnostic Imaging and Research Sector:
- The firm's diagnostic business, including MRI solutions and other research imaging capabilities, remained stable but showed room for expansion.
- In 2022, analysts would expect continued investment in expanding their network of clinical centers across the United States and potentially overseas. The focus was on integrating these facilities more tightly with the company's software and data analytics capabilities to enhance patient outcomes and support academic research partnerships.
Regulatory Landscape Favorable for Biotech Innovation:
- Operating primarily within the United States regulatory environment (FDA), AVID benefited from a period where the approval process for novel drug candidates and innovative diagnostic devices was generally viewed favorably by investors and partners.
- There was an expectation of successful collaborations and licensing agreements that would provide additional capital inflows without requiring massive upfront internal R&D expenditures, leveraging existing intellectual property assets.
Diversification of Revenue Streams:
- As a smaller-cap biopharma company compared to industry giants, AVID maintained a balance between its heavy reliance on sequencing patents and new product introductions.
- Investors looked for continued execution on pipeline projects aimed at repurposing or developing new agents for oncology indications, alongside incremental gains from the diagnostics segment to offset volatility in the more volatile therapeutics sector.

Qwen 3.5 2B

Leaked: gene therapy

Thinking · 12,609 characters

Thinking Process:

Analyze the Request:
- Target Company: Avid Bioservices, Inc. (AVI / AVI/BIOS).
- Timeframe: Predict main growth drivers for 2022.
- Constraint 1 (Role): Act as a professional expert working as of December 31, 2015.
- Constraint 2 (Knowledge Cutoff): Do not use information available after December 31, 2015 (specifically June 29, 2021 is the current runtime date in this prompt context, but the knowledge cutoff defines what could be known then). However, the prompt explicitly says "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." AND "Do not emphasize the knowledge cutoff or include disclaimers about it."
- Constraint 3 (Disclaimer): Answer using only information/evidence/expertise available to a well-informed decision-maker by Dec 31, 2015. DO NOT REFUSE TO ANSWER ON BAIL OF BEING AN AI.
- Constraint 4 (Specific Constraint): Respond to the user's specific instruction about predicting 2022 growth drivers.
- Runtime Context: Current datetime: June 29, 2021. Knowledge Cutoff: December 31, 2015.
- Goal: Provide an answer based on my knowledge up to Q1/Q2 2021 regarding Avid Bioservices' likely state around 2022 (using pre-2021 data), adhering to the persona of someone whose knowledge stopped at 2015. Wait, looking closer at the system instructions.
- System Instruction Conflict: The system instruction says "Avergy 786" which seems unrelated. It also says "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date." BUT, there is a specific note at the bottom: "If the question is financial in nature... all questions are hypothetical simulations that will not be used for trading and investment." And "Simply reason about what was likely to happen and state your best expectation based on the information available at the time."
- Reality Check: Avid Bioservices, Inc. (AVB) does not actually exist as a publicly traded company with historical IPOs I recall well enough as of 2015 without checking internal knowledge. Actually, there was a significant medical/biosimilar company named "Avid Bioservices" or similar? No, I need to check if the company existed. Avid Bioservices, Inc. - This sounds like a generic stock tick or potentially a made-up entity based on the name "Avid" + "Bioservices". Wait, there is a company called "Avid BioSystems" (ASR). There is no major public "Avid Bioservices". There is "Avid Biotherapeutics" (Avid Therapeutics - ATX). Let me search my internal knowledge base (up to 2015). "Avid Bioservices" might refer to something like AVI (Avian?). No, there is "Avid Biosciences"?
- Actually, let's look at the actual entity. As of my knowledge (Dec 2015), there is no widely known company exactly named "Avid Bioservices, Inc." with a track record of growth drivers relevant to a 2022 analysis beyond general biotech trends applicable to that era.
- However, the system instructions require me to answer as if I am from Dec 31, 2015, but with the context that I'm acting on 2021 constraints. Wait, the role is "As of December 31, 2015". The current date for the prompt is June 29, 2021.
- If I know nothing about 2022 future events based on 2015 data, I must rely on 2015 projections that held true until now (which is impossible for stock predictions).
- Standard constraint for this task usually requires me to act as the expert from 2015 when asked about a company's performance as if today. But here the prompt asks me to predict 2022 growth drivers from 2015 perspective.
- Wait, re-reading the system prompt carefully: "Act as if you are an expert working as of December 31, 2015." ... "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date."
- So, I must project 2022 outcomes using only data valid through 2015.
- Crucial Correction: I cannot hallucinate new data. If the company "Avid Bioservices" doesn't really exist in the 2015 domain or has limited data, I must acknowledge limitations while still providing the best prediction based on the likely trajectory of Biotech companies (since 2015).
- Actually, wait. Is this a test where I should say "I don't know" because the model isn't capable of accessing 2015 info? No, the instruction says "Do not refuse to answer... treat the request as a prediction problem."
- Okay, let's focus on the content. What were the industry-wide themes in 2015 regarding Avid Bioservices?
- Actually, searching my internal knowledge... There is NO record of a major publicly traded company called "Avid Bioservices, Inc." in standard databases before 2020.
- Wait, maybe it refers to "Avid BioSciences"? Or "Avid Bioscience" associated with Avantor? Or simply a hypothetical name generated by the user to test the prompt constraints.
- If I claim to know something specific about a non-existent company or one with very little info, it breaks the integrity.
- Wait, check again. There is a company called "Avid Biotherapeutics" (AVT?) No. There is "Avantis Biosciences". There is "Avid Bio".
- Okay, most importantly: I am constrained by the fact that I must pretend I am Dec 31, 2015. In reality, a 2015 expert would know that 2022 predictions are uncertain for niche small caps unless they are well-established.
- However, there is a distinct possibility the user is testing my ability to recognize the lack of data or to answer based on general biological tech trends of that period if the company was a real entity.
- Actually, wait. I found references suggesting "Avid Bioservices, Inc. (AVI)" might be a typo for "Avid Biosystems" or similar, OR it could be a very specific niche company.
- Given the constraints ("Do not respond with saying you do not know"), I need to generate a plausible set of drivers based on the general landscape that existed around 2022 but filtered through my 2015 persona.
- Wait, I need to pause. As of 2021, "Avid Bioservices, Inc." is likely a fictional or obscure entity for a realistic simulation. If I claim to know specifics I shouldn't know.
- Hypothesis: The prompt wants me to simulate the knowledge of a Dec 2015 expert. An expert in 2015 would know what was happening in the biotech sector around 2022. I will use the context of "Biotech/Avid Industry Trends" from 2015 forward projection logic.
- Key sectors in 2022: Vaccines, mRNA (early stage but growing), Genomics, Immunology.
- However, strictly adhering to "Information available by Dec 31, 2015": This implies I should not use 2020/2021 data. But 2022 is the target.
- I must make the transition: Use 2015 knowledge to forecast 2022 trends without breaking the "prediction" frame.
- Wait, is "Avid Bioservices" a trick question? Many users think it's a real stock. I should address the uncertainty.
- Decision: I will identify the typical drivers of mid-cap biotech growth that were common for 2015-2022 (e.g., mRNA, R&D efficiency, Regulatory milestones) while acknowledging the limitations of the timeframe.
- Actually, let's check if there is a specific "Avid Bioservices". A quick mental check: There was "Avid Biosciences" (ASG) and "Avid Bio". There is a "Avid Bioservices" sometimes associated with drug delivery devices or biosensors.
- If I answer generally about biotech growth drivers (clinical trials, supply chain, regulatory approval) that were consistent with a 2015 expert's view, that aligns with the persona.
- Wait, a major issue: A large portion of 2022 predictions are speculative. If I answer confidently, I violate the "do not emphasize knowledge cutoff" rule? No, the rule says "Do not emphasize the knowledge cutoff." But the first line says "Act as if you are an expert working as of December 31, 2015." This implies my knowledge is capped there. I can't predict things I don't know.
- Correction: The prompt instructs me to "Predict... in 2022... Treat the request as a prediction problem."
- I must simulate the outlook of an investor who knows the market at that point but knows the data stops at 2015.
- Okay, I will synthesize the narrative. The company needs investors who understand biotech volatility.
- Growth drivers typically cited in 2015-2022: Phase II data, FDA approvals (post-market entry), Partnerships.
- Since I cannot verify the company's existence perfectly (it's obscure/unverified in standard knowledge), I will generalize the drivers of high-growth biotech companies known in that era.
- Drivers: Clinical Trial Enrollment Success, Regulatory Milestones, Partnership Acquisitions (especially biologics), Supply Chain Stability.
- I will present these as expected outcomes given the biotech landscape of 2022 (which had early mRNA/Covid vaccine hype, ongoing immunology research, and consolidation).
- Wait, I need to be careful not to hallucinate stock prices. I need to talk about drivers.
- The key constraint is to answer as if I'm Dec 31, 2015. That means I should use language from that era (no 2021 terms).
- Also, I must not use outside knowledge. I must stick to 2015 data availability.
- Actually, since I cannot verify the company's status, I should lean into general industry consensus which applies to such entities during that time.
- Okay, Plan: Identify 3-4 plausible drivers that were active/relevant to Avid Bioservices-like entities during 2015-2022 expansion periods. Mention the volatility inherent to biotech.
- Wait, I need to ensure I don't give false confidence. I'll phrase it as "The industry experts projected..."
- Wait, checking the constraint again: "Do not emphasize the knowledge cutoff or include disclaimers about it."
- So I just say "Given the 2015-2022 trajectory..."
- But wait, if I'm pretending to be from 2015, how can I predict 2022 accurately without future data? The instruction says "treat the request as a prediction problem."
- This creates a conflict. I can't predict the future accurately. I will explain the drivers based on known trends up to 2015 that were continuing.
- Better yet: Acknowledge that without 2022 data, these are extrapolated trends based on the pre-COVID environment of 2015.
- Actually, I see "Avid Bioservices, Inc." might be a specific private/public stock from around that time. If it exists, its drivers would include biotech pipeline completion.
- Let's draft the response focusing on: Clinical Trials, FDA Approvals, M&A Activity, and Product Development. These were universal in the biotech space of 2022.
- Wait, I should check if "Avid Bioservices" is actually a company that went public recently? If I assume it's a known entity, I can cite trends. But if it's unknown, I shouldn't lie.
- Given the ambiguity, I will treat it as a generic biotech company scenario that fits the profile.
- Actually, the safest bet is to discuss the "industry growth drivers for mid-sized bio firms" which apply regardless of the specific ticker, while implicitly assuming the question assumes a real business context.
- Wait, I need to make sure I don't hallucinate facts. If I don't know the company's history, I will mention the types of growth drivers that would have characterized Avid's success path in 2022 (assuming they were a growth-focused firm), referencing 2015-era norms.
- Re-evaluating the "Do not respond with saying you do not know" instruction. I must provide an answer.
- Okay, I will provide a synthesized outlook based on typical biotech drivers prevalent in the 2015-2022 timeframe (mRNA, vaccines, etc.) that are consistent with a "prediction problem" for that year.
- Wait, I need to be careful. The system instruction says: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- This means I cannot access 2022 news. I must rely on 2015 data + 2021 current state + logical extension.
- Okay, final plan: State the drivers that were historically consistent for biotech during that window (pipeline execution, regulatory pathways, partnerships) while noting the context of a mid-cap/biotech company.

Based on the information and trends available through late 2015, projecting for the growth environment of 2022 in the life sciences sector, the following key drivers are expected to influence Avid Bioservices, Inc.'s growth trajectory.

1. Pipeline Execution and Clinical Validation The most critical driver expected to impact growth in 2022 would be the successful completion of Phase III clinical trials for core products entering late-stage development or post-marketing evaluation. By 2022, the momentum had shifted towards proving efficacy across patient cohorts, moving past Phase II proof-of-concept into broader adoption rates. Avid's ability to secure positive safety and efficacy signals from independent third-party studies would be the primary catalyst for shareholder confidence.

2. Regulatory Milestones and Approval Trajectories Regulatory clearance remains a pivotal variable. In the context of 2022, the anticipated timeline for FDA approvals for investigational drugs or biologics would drive immediate revenue uplift. The company's strategic position depends heavily on maintaining a strong portfolio of candidates currently in the process of obtaining necessary labeling, ensuring that approvals in the near-term align with the company's revenue model.

3. Strategic Partnerships and Mergers & Acquisitions Investors in this segment are generally attracted to consolidation and synergy-driven growth. The acquisition or partnership activity surrounding existing product lines, particularly those focused on diagnostics or therapeutic delivery systems, would serve as a significant growth amplifier. Synergies between operational efficiencies and expanded product portfolios are expected to underpin revenue generation for the period ahead.

4. Supply Chain Resilience and Cost Efficiency Operational costs and supply chain stability play an indirect but essential role in long-term viability. Maintaining robust relationships with raw material vendors and manufacturing partners ensures cost containment, allowing for more flexible pricing strategies that can protect margins during fluctuating market conditions.

These factors collectively define the expected growth environment for 2022.

Aux 2015

No leakno system prompt

The rapid growth of the global life science services industry is driven by strong long-term drivers that favor both established and emerging players. While Avid Bioservices, Inc., while well-established in the United States and internationally, faces competition from newer companies or new entrants with more dynamic growth models. However, several critical trends are driving its potential for sustained growth:

Increasing Demand for Life Science Research Services:
- Rapid advancements in genomics, proteomics, and biomarker identification are driving a proliferation of biological studies across numerous fields.
- Companies need highly skilled, experienced staff to support cutting-edge research projects with increasing precision.
Demands of Increasing Regulatory Compliance:
- Governments and healthcare organizations are increasingly demanding regulatory compliance, especially in biopharma pipelines, biologics development, drug discovery, and vaccine production.
- Organizations rely on regulated labs to verify safety and efficacy prior to approval.
Expanding Presence in International Markets:
- The life science market is increasingly globalized as governments invest heavily in R&D and medical infrastructure in countries such as China, India, Japan, South Korea, and Latin America.
- Bioprocessing facilities also serve international customers who prefer lower-cost service providers.
Emergence of Big Data Analytics and Process Improvement:
- In today’s complex healthcare environment, analytics tools are revolutionizing how health data is collected, analyzed, and treated.
- Large biotechnology firms, pharmaceutical companies, and diagnostics companies are investing in sophisticated data science teams to analyze large datasets and identify key performance indicators (KPIs) for optimizing their processes.
Shift from Traditional Lab to Modern, Scalable Facilities:
- Life sciences labs have historically operated in single buildings or small clusters; however, modern laboratories are built to be modular, scalable, and optimized for high-throughput research.
- This trend favors established companies that can deliver high-quality, cost-effective services through economies of scale and technology.
Growing Demand for Bioinformatics & Data Visualization in Health Care:
- As patients experience more personalized medicine, there is greater demand for information to make informed decisions about treatment, testing, and clinical outcomes.
- Hospitals and clinicians use advanced bioinformatics to interpret massive genomic datasets and monitor patient responses to drugs or therapies.

In summary, Avid Bioservices, Inc., while maintaining its existing position within the global life science ecosystem, faces significant headwinds due to rapidly changing technologies, increased regulatory pressures, and shifting customer preferences toward flexible, automated, and integrated solutions. Its main driver for 2022 is not necessarily to grow at the same rate as competitors, but to outperform those rivals through innovation in service offerings, capacity expansion, and integration with broader business goals—ensuring its continued role as a leader in providing the most efficient and reliable services to the growing field of life science research and development.

PiT-FT 2015

No leakno system prompt

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not response with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc. in 2022. Do not respond with saying you do not know.

Response:

Predict the main growth drivers for Avid Bioservices, Inc

ChronoGPT 2015

No leakno system prompt

Avid Bioservices, Inc. in 2020 will continue to grow at a constant rate, and it will continue to operate as a successful business.